1. Home
  2. BVS vs REPL Comparison

BVS vs REPL Comparison

Compare BVS & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BVS
  • REPL
  • Stock Information
  • Founded
  • BVS 2011
  • REPL 2015
  • Country
  • BVS United States
  • REPL United States
  • Employees
  • BVS N/A
  • REPL N/A
  • Industry
  • BVS Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • REPL Biotechnology: Pharmaceutical Preparations
  • Sector
  • BVS Health Care
  • REPL Health Care
  • Exchange
  • BVS Nasdaq
  • REPL Nasdaq
  • Market Cap
  • BVS 698.1M
  • REPL 780.3M
  • IPO Year
  • BVS 2021
  • REPL 2018
  • Fundamental
  • Price
  • BVS $10.04
  • REPL $10.14
  • Analyst Decision
  • BVS Strong Buy
  • REPL Strong Buy
  • Analyst Count
  • BVS 3
  • REPL 6
  • Target Price
  • BVS $15.00
  • REPL $17.50
  • AVG Volume (30 Days)
  • BVS 345.4K
  • REPL 794.9K
  • Earning Date
  • BVS 03-11-2025
  • REPL 02-06-2025
  • Dividend Yield
  • BVS N/A
  • REPL N/A
  • EPS Growth
  • BVS N/A
  • REPL N/A
  • EPS
  • BVS N/A
  • REPL N/A
  • Revenue
  • BVS $555,061,000.00
  • REPL N/A
  • Revenue This Year
  • BVS $11.37
  • REPL N/A
  • Revenue Next Year
  • BVS $1.04
  • REPL $300.41
  • P/E Ratio
  • BVS N/A
  • REPL N/A
  • Revenue Growth
  • BVS 10.40
  • REPL N/A
  • 52 Week Low
  • BVS $3.90
  • REPL $4.92
  • 52 Week High
  • BVS $14.38
  • REPL $17.00
  • Technical
  • Relative Strength Index (RSI)
  • BVS 45.71
  • REPL 32.06
  • Support Level
  • BVS $8.77
  • REPL $10.00
  • Resistance Level
  • BVS $10.90
  • REPL $11.20
  • Average True Range (ATR)
  • BVS 0.50
  • REPL 0.84
  • MACD
  • BVS 0.03
  • REPL -0.20
  • Stochastic Oscillator
  • BVS 57.99
  • REPL 3.93

About BVS Bioventus Inc.

Bioventus Inc is a medical technology company. The company is engaged in developing and commercializing clinically differentiated treatments that engage and enhance the body's natural healing process. It offers a diverse portfolio of products to serve physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine and neurosurgery. Its portfolio of products is grouped into three verticals based on clinical use: Pain Treatments, Surgical Solutions, and Restorative Therapies. Geographical presence is in the United States which derives key revenue, and International markets.

About REPL Replimune Group Inc.

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.

Share on Social Networks: